Renalytix Plc (RNLX) Directors and Executive Officers - CSIMarket
CSIMarket
 
Renalytix Plc  (RNLX)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare

Renalytix Plc

Officers & Directors


James McCullough
Chief Executive Officer and Chairman of the Board

Christopher Mills
Director

Joel R. Jung
Interim Chief Financial Officer

CohnRenzick LLP
We have served as the Company

Daniel J. Levangie
Director

Fergus Fleming
Chief Technology Officer and Director

Erik Lium
Director

Catherine Coste
Director ,

Renalytix Plc currently has 52 employees.

  News about Renalytix Plc Key Personnel

Revolutionizing Kidney Disease Management: KidneyIntelX Recognized in Final KDIGO 2024 Clinical Guideline



Chronic Kidney Disease (CKD) affects millions of people worldwide and imposes a significant burden on healthcare systems globally. As we enter a new era of personalized medicine, risk prediction and tailored treatment plans are crucial in managing this complex and widespread condition. The inclusion of KidneyIntelX in the Final KDIGO 2024 Clinical Guideline for CKD is a landmark moment, as it highlights the imperative need for advanced risk assessment tools in optimizing patient care and reducing the risk of progression to end-stage renal disease (ESRD). This article explores the significance of this development and the potential impact it holds for the future.
Risk Prediction and Personalized ...






RNLX Management Effectiveness RNLX Revenue per Employee RNLX Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.